Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort.
Adcetris
Autologous stem cell transplantation
Brentuximab vedotin
CHOEP
CHOP
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
07
03
2021
accepted:
28
04
2021
pubmed:
27
5
2021
medline:
6
8
2021
entrez:
26
5
2021
Statut:
ppublish
Résumé
Brentuximab vedotin (BV)-CHP is the new standard regimen for first-line treatment of systemic anaplastic large cell lymphoma (sALCL). We undertook a retrospective analysis of consecutive patients diagnosed with sALCL, treated in routine practice, to serve as a benchmark analysis for comparison BV-CHP efficacy in routine practice. Patients aged 16 years or older with sALCL treated in seven UK and Australian centres and from 14 additional centres from the UK Haematological Malignancy Research Network database (n = 214). Treatment allocation was clinician choice and included best supportive care (BSC). Main outcomes were time to treatment failure (TTF) and overall survival (OS). Multivariable analysis for predictors of both TTF and OS was also undertaken. The median age 52 years (range 16-93), 18% ECOG ≥ 3 and 40% of cases were ALK positive. CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) was employed in 152 (71%) of patients and CHOEP (CHOP + etoposide) in 4% of patients. For CHOP-treated patients overall response rate (ORR) was 65% and complete response (CR) 47%. Only 9% of patients underwent autologous stem cell transplant (ASCT). With 57 months median follow-up, 4-year TTF and OS were 41.2% (95% CI 33.1-49.1) and 58.9% (95% CI 50.3-66.5) respectively. Multivariable analysis showed ALK+ status was independently associated with superior TTF (HR 0.36, 95% CI 0.21-0.63) but not OS (0.44, 95% CI 0.18-1.07). We present a retrospective analysis with mature follow-up of one of the largest multicentre populations of sALCL available, comparable to similar large retrospective studies. ALK status remains a strong predictor of outcomes. These data serve as a robust benchmark for BV-CHP as the new standard of care for sALCL. Similar real-world evidence with BV-CHP will be desirable to confirm the findings of ECHELON-2.
Identifiants
pubmed: 34037958
doi: 10.1007/s12325-021-01764-0
pii: 10.1007/s12325-021-01764-0
pmc: PMC8280044
doi:
Substances chimiques
Immunoconjugates
0
Brentuximab Vedotin
7XL5ISS668
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
3789-3802Subventions
Organisme : Blood Cancer UK
ID : 15037
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 29685
Pays : United Kingdom
Informations de copyright
© 2021. The Author(s).
Références
Moskowitz AJ, Lunning MA, Horwitz SM. How I treat the peripheral T-cell lymphomas. Blood. 2014;17(123):2636–44.
doi: 10.1182/blood-2013-12-516245
Sibon D, Fournier M, Briere J, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte trials. J Clin Oncol. 2012;32(30):3939–46.
doi: 10.1200/JCO.2012.42.2345
Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;12(111):5496–504.
doi: 10.1182/blood-2008-01-134270
Gleeson M, Peckitt C, Cunningham D, et al. Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital. Leuk Lymphoma. 2018;7(59):1586–95.
doi: 10.1080/10428194.2017.1393671
Savage KJ, Chhanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;10(15):1467–75.
doi: 10.1093/annonc/mdh392
Dearden CE, Johnson R, Pettengell R, et al. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol. 2011;4(153):451–85.
doi: 10.1111/j.1365-2141.2011.08651.x
Shustov A, Cabrera M, Bellei M, et al. Anaplastic large cell lymphoma, ALK-negative: analysis of 235 cases collected by the T-cell project. Hematol Oncol. 2019;S2(37):283–4.
doi: 10.1002/hon.93_2630
Shustov A, Cabrera ME, Civallero M, et al. ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project. Blood Adv. 2021;3(5):640–8.
doi: 10.1182/bloodadvances.2020001581
Cederleuf H, Bjerregard Pedersen M, Jerkeman M, et al. The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: a Nordic Lymphoma Group study. Br J Haematol. 2017;5(178):739–46.
doi: 10.1111/bjh.14740
Sibon D, Nguyen DP, Schmitz N, et al. ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. Haematologica. 2019;12(104):e562–5.
doi: 10.3324/haematol.2018.213512
d’Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;25(30):3093–9.
doi: 10.1200/JCO.2011.40.2719
Chihara D, Pro B, Loghavi S, et al. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2015;4(171):509–16.
doi: 10.1111/bjh.13628
Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;18(30):2190–6.
doi: 10.1200/JCO.2011.38.0402
Fanale MA, Horwitz SM, Forero-Torres A, et al. Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. Blood. 2018;19(131):2120–4.
doi: 10.1182/blood-2017-12-821009
Horwitz S, O’Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;10168(393):229–40.
doi: 10.1016/S0140-6736(18)32984-2
Smith A, Crouch S, Lax S, et al. Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK’s Haematological Malignancy Research Network. Br J Cancer. 2015;9(112):1575–84.
doi: 10.1038/bjc.2015.94
Cederleuf H, Pedersen MB, Jerkeman M, et al. Addition of etoposide to CHOP is associated with improved outcome in adult anaplastic large cell lymphoma patients: a Nordic Lymphoma Group Study. Blood. 2015;23(126):340.
doi: 10.1182/blood.V126.23.340.340
Wunderlich A, Kloess M, Reiser M, et al. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin’s lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Ann Oncol. 2003;6(14):881–93.
doi: 10.1093/annonc/mdg249
Abramson JS, Feldman T, Kroll-Desrosiers AR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014;11(25):2211–7.
doi: 10.1093/annonc/mdu443
Sieniawski M, Angamuthu N, Boyd K, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood. 2010;18(115):3664–70.
doi: 10.1182/blood-2009-07-231324
Corradini P, Marchetti M, Barosi G, et al. SIE-SIES-GITMO guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias. Ann Oncol. 2014;12(25):2339–50.
doi: 10.1093/annonc/mdu152
Kharfan-Dabaja MA, Kumar A, Ayala E, et al. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T Cell and NK/T cell lymphomas: an international collaborative effort on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017;11(23):1826–38.
doi: 10.1016/j.bbmt.2017.07.027
Savage KJ, Horwitz SM, Advani RH, et al. An exploratory analysis of brentuximab vedotin plus CHP (A+CHP) in the frontline treatment of patients with CD30+ peripheral T-cell lymphomas (ECHELON-2): impact of consolidative stem cell transplant. Blood. 2019;Supplement_1(134):464.
Fossard G, Broussais F, Coelho I, et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2018;3(29):715–23.
doi: 10.1093/annonc/mdx787
Mercadal S, Briones J, Xicoy B, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol. 2008;5(19):958–63.
doi: 10.1093/annonc/mdn022
Yam C, Landsburg DJ, Nead KT, et al. Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas. Am J Hematol. 2016;7(91):672–6.
doi: 10.1002/ajh.24372
Park SI, Horwitz SM, Foss FM, et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study. Cancer. 2019;9(125):1507–17.
doi: 10.1002/cncr.31861
N, Tomita, Hattori Y, Fujisawa S, et al. Post-therapy
doi: 10.1007/s00277-014-2227-5
El-Galaly TC, Pedersen MB, Hutchings M, et al. Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: a review of 124 patients. Am J Hematol. 2015;11(90):975–80.
doi: 10.1002/ajh.24128